Lipid Nanoparticle Raw Materials Market: Impact of Personalized Medicine on Market Development
The global lipid
nanoparticle raw materials market size was valued at USD 224.37 million in
2025. The market is projected to account for an 5.8% CAGR from 2026 to 2034.
Analyst Commentary on Market Growth
Polaris Market Research analysts point to the expanding use
of lipid nanoparticles in drug development as the central force behind market
growth. Their ability to carry medicines to targeted areas of the body is
lifting demand for the lipids, surfactants, polymers, and stabilizers used to
make them. Analysts see the strongest opportunity for suppliers that pair
consistent raw material quality with flexible formats, such as ready-to-use
kits, as developers move from research into therapeutic production. They also
caution that complex manufacturing and competition from exosomes, liposomes,
and dendrimers could temper adoption.
Lipid Nanoparticle Raw Materials Market Statistics at a
Glance
- 2026
Market Size: USD 237.26 Million
- 2036
Projected Size: USD 372.48 Million
- CAGR
(2026–2034): 5.8%
Key Growth Drivers, Major Companies and Segments Covered
Growth Drivers: The rising incidence of lung
diseases, increasing adoption of mRNA technology across therapeutic
formulations, and intensifying research into targeted drug delivery are the
primary forces behind the market's expansion, alongside growing demand for
ionizable lipids. In June 2023, Bayer AG entered a collaboration framework with
Acuitas Therapeutics to expand its gene therapy offering with lipid
nanoparticle technology.
Restraints and Challenges: The complexity of lipid
nanoparticle production is a major restraint, as intrinsic instability can
limit delivery effectiveness and dampen demand for raw materials. Superior
substitutes such as exosomes, liposomes, and dendrimers, along with higher
manufacturing costs, may also slow adoption.
Major Companies Covered: Avanti Polar Lipids,
Biopharma PEG Scientific, BroadPharm, CordenPharma International, Creative
Biolabs, Echelon Biosciences, Merck KGaA, NOF America Corporation,
Polysciences, and Tebu Bio.
Competitive Landscape: The market is fragmented, and
major players are stepping up partnerships, collaborations, and acquisitions to
build capacity as demand for lipid nanoparticles increases.
Research Momentum: Scientific progress continues to
widen the addressable base. An October 2023 study in the Proceedings of the
National Academy of Sciences described a lipid nanoparticle that delivers mRNA
to targeted muscle while limiting off-target effects, and a 2023 study explored
mRNA and lipid nanoparticles for treating blindness. Researchers also developed
a lipid nanoparticle-based CRISPR carrier system in March 2023.
Segments Covered: By Product (ionizable lipids,
reagents, other raw materials), By Disease Indication (cancer, infectious
diseases, blood diseases), By Application (therapeutics, research), By End Use,
By Region.
Segment Highlights: The report highlights the kits
format as the fastest-growing product area, driven by compatibility with
vaccine and gene therapy workflows and the customization flexibility it offers
researchers. Therapeutics held a significant revenue share in 2023, and
pharmaceutical and biotechnology companies are expected to record significant
end-use growth as investment in lipid nanoparticle capabilities rises.
👉 Download a Free Sample
of the Lipid Nanoparticle Raw Materials Market Report →
https://www.polarismarketresearch.com/industry-analysis/lipid-nanoparticle-raw-materials-market
Recent Developments in the Industry
- April
2024: NOF Corporation partnered with Phosphorex to offer lipid
nanoparticle formulations built on its proprietary COATSOME 8 SA Series
ionizable lipid.
- March
2024: CordenPharma unveiled lipid nanoparticle starter kits designed for
producing mRNA therapies.
- February
2024: Evonik Industries collaborated with the University of Mainz to
commercialize novel PEG lipids for nucleic acid delivery.
- July
2023: Genentech entered a collaboration with Berkeley Lab to advance
production of new lipid nanoparticles for drug development.
- October
2023: BIOVECTRA entered a service agreement with Acuitas Therapeutics to
deliver distinct lipid nanoparticles for mRNA-based therapeutics.
- July
2023: McGill University and Moderna expanded their collaboration on lipid
nanoparticle research projects.
Regional Snapshot: North America Leads, Asia Pacific Set
for Rapid Growth
North America held the largest share in 2023, supported by
prominent pharmaceutical and biotechnology companies investing heavily in drug
discovery, including a May 2023 NIH Phase I SBIR grant awarded to Aphios
Corporation for COVID-19 mRNA vaccine development. Asia Pacific is expected to
grow at a rapid pace, as the rising prevalence of blood diseases increases
demand for targeted-delivery treatments and the raw materials behind them.
Sanofi's USD 25 million grant to an MIT laboratory in April 2023 for RNA
therapies and vaccines shows the scale of funding reaching the field.
Why It Matters for Suppliers Evaluating the Market
Forecast to 2032
For stakeholders researching top companies and the
Lipid Nanoparticle Raw Materials Market forecast to 2032, the
underlying report benchmarks market share, company positioning, and
segment-level forecasts to support sourcing, partnership, and investment
decisions. It also includes Porter's Five Forces, PESTEL, and value chain analysis.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research
and consulting firm offering 5,000+ published reports across 20+ industry
verticals, delivering data-backed insights to help businesses make informed
decisions.
More Trending Latest Reports By Polaris Market Research:
top-electronics-manufacturing-services-companies-worldwide
Comments
Post a Comment